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Polyglutamine diseases are fatal neurological disorders that affect the central nervous
system. They are caused by mutations in disease genes that contain CAG trinucleotide
expansions in their coding regions. These mutations are translated into expanded
glutamine chains in pathological proteins. Mutant proteins induce cytotoxicity, form
intranuclear aggregates and cause neuronal cell death in specific brain regions. At
the moment there is no cure for these diseases and only symptomatic treatments
are available. Here, we discuss novel therapeutic approaches that aim in neuronal cell
replacement using induced pluripotent or adult stem cells. Additionally, we present the
beneficial effect of genetically engineered mesenchymal stem cells and their use as
disease models or RNAi/gene delivery vehicles. In combination with their paracrine and
cell-trophic properties, such cells may prove useful for the development of novel therapies
against polyglutamine diseases.
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Polyglutamine Diseases
Polyglutamine (polyQ) diseases are late-onset progressive neurodegenerative disorders; they
include Huntington’s disease (HD), Dentatorubral-pallidoluysian atrophy (DRPLA), Spinal and
bulbar muscular atrophy (SBMA), and Spinocerebellar ataxia (SCA)−1,−2,−3,−6,−7, and−17.
They are caused by a trinucleotide (CAG) repeat expansion within the coding region of unrelated
genes that do not seem to share a common function or conformation. With the exception of
SBMA, mutant genes are inherited in an autosomal dominant manner. CAG expansions encode
for longer polyQ chains in the produced protein (Orr, 2012). As a result, the mutant protein
adopts a different conformation than the wild type protein which is accompanied by a loss
of its functionality. A striking feature of the polyQ protein is its ability to form toxic species
and misfold into oligomers that slowly aggregate into inclusions detected in the nucleus. PolyQ
expansions in mutant proteins may be deleterious because they interfere with normal protein-
protein interactions or mediate aberrant ones (Lam et al., 2006; Lim et al., 2008), resulting in
loss or gain of function, respectively. Protein accumulation in the nucleus may also perturb the
structure of protein complexes, leading to transcriptional changes and contributing to toxicity
Abbreviations: polyQ, polyglutamine; HD, Huntington’s disease; DRPLA, Dentatorubral-pallidoluysian atrophy; SBMA,
Spinal and bulbar muscular atrophy; SCA, Spinocerebellar ataxia; PC, Purkinje cell; iPSC, Induced pluripotent stem cell;
MSC, Mesenchymal stem cell; ATXN1, ataxin-1; YFP, Yellow Fluorescent Protein; ES, embryonic cells; MUSE, multilineage
differentiating stress enduring cells; MSN, medium spiny neuron; NPC, neural precursor cell; NTF-MSCs, neurotrophic
factors-secreting MSCs; QA, quinolinic acid; GE-MSCs, genetically engineered MSCs; HTT, huntingtin.
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in neurons. This hypothesis is supported by the recruitment of
transcription factors into polyQ protein aggregates (Shimohata
et al., 2000). Despite wide expression of mutant genes, formation
of aggregates is accompanied by selective neurodegeneration. For
example, in the case of SCA1 neuronal loss is mostly obvious in
the Purkinje cell (PC) layer of the cerebellum (Orr and Zoghbi,
2001).
The symptoms of the disease manifest around the fourth
decade of the life depending on the length of the polyQ tract
in mutant proteins. The protein degradation machinery plays a
pivotal role in the cellular response to expanded polyQ chains
(Cummings et al., 1999; Bence et al., 2001). Chaperones bind
to the misfolded proteins but fail to prevent their aggregation
(Schmidt et al., 2002). Ubiquitinated forms of polyQ proteins are
persistently associated with proteasome components indicating
that cells are attempting to destroy misfolded proteins and that
these substrates may be resistant to proteasomal degradation
(Schmidt et al., 2002). Experimental evidence indicate that polyQ
aggregates increase oxidative stress which may be responsible
for the inhibition of proteasome activity (Diaz-Hernandez et al.,
2006). In contrast, overexpression of proteins participating in
the ubiquitin-proteasome complex protects cells and transgenic
mice from polyQ-induced degeneration (Torashima et al., 2008;
Petrakis et al., 2012b). These findings indicate that polyQ diseases
are associated with a gradual inability of the cellular protein
degradation machinery to remove misfolded proteins.
Stem Cell Models of polyQ Diseases
Cell models resembling the features of polyQ diseases are
necessary in order to define the exact mechanisms of
neuronal degeneration. Such models should present polyQ-
induced cytotoxicity and intranuclear protein aggregation in
a measurable manner and could be used for the identification
of small molecules that would reverse these biochemical
procedures. Immortalized laboratory cell lines as COS-1 or
HEK have been extensively used for such purposes. However,
they may not represent ideal models as they have evolved
high chaperone activity under selective pressure in culturing
conditions.
Induced pluripotent stem cells (iPSCs) have recently emerged
as excellent tools for cell-based assays since they can differentiate
into neuronal cell populations. Using fibroblasts from polyQ-
disease patients, researchers have generated iPSC-derived
neurons for SCA2, SCA3, HD, and SBMA (Koch et al., 2011;
Camnasio et al., 2012; Xia et al., 2012; Nihei et al., 2013). These
cells exhibit disease-associated changes in electrophysiology and
metabolism due to polyQ expansions of the mutant proteins
(HD iPSC Consortium, 2012). The iPSC technology holds great
promise for cell biology and drug discovery. Researchers are
expected to overcome current limitations in cell generation and
proliferation. They will be also able to solve problems associated
with genetic heterogeneity of fibroblasts obtained from different
patients and carefully select cell lines with little risk for tumor
formation. However, iPSC-derived neurons may not express a
robust disease-associated phenotype, such as protein aggregates,
that would facilitate their use in large high-throughput assays.
Mesenchymal stem cells (MSCs) represent a complementary
alternative to iPSCs in terms of disease modeling. These adult
stem cells can be easily isolated from various tissues (e.g.,
Wharton’s jelly or adipose tissue) and expanded ex-vivo in large
numbers (Pittenger et al., 1999). MSCs have a differentiation
potential toward mesodermal cell lineages, even though under
specific culturing conditions, they adopt characteristics of cells
belonging to other germ layers (Kuroda et al., 2010). Recently,
Dossena et al. (2014) showed thatMSCs isolated from the adipose
tissue of SBMA patients, partially form nuclear polyQ inclusions
upon chemical inhibition of the proteasome. These findings
suggest that a decline in proteasomal activity favors the gradual
deposition of polyQ proteins in the nucleus.
Would it be possible to produce a robust pathogenic polyQ
phenotype in MSCs? To this end, we generated an inducible
mesenchymal stem cell model for the polyQ disease SCA1
using the Sleeping Beauty transposon system (Petrakis et al.,
2012a). These cells stably overexpress the mutant gene ataxin-1
(ATXN1Q82) in fusion with Yellow Fluorescent Protein (YFP)
under the Tet-On promoter. We expected that overproduction
of the polyQ protein would result in a clear and measurable
phenotype, such as large intranuclear protein aggregates. YFP-
ATXN1Q82 MSCs stably express the mutant protein and
accumulate large YFP-positive protein aggregates in the nucleus
(Figure 1). YFP-ATXN1Q82 MSCs seem to retain their stem
cell properties, such as fibroblastic morphology, self-renewal,
proliferative capacity and expression of MSC surface markers
(data not shown). The differentiation of YFP-ATXN1Q82 MSCs
toward neuron-like cells would generate a population with a
robust neuronal aggregation phenotype.
The efficient neuronal differentiation of MSCs is a matter of
debate. Available protocols use chemical substances, cytokines
or a combination of them to induce the formation of neuron-
like cells. However, in several cases the obtained phenotypes are
subtle and differentiated MSCs have limited electrophysiological
properties and functionality. Therefore, breaking the barrier
of the mesenchymal cell fate and directing MSCs toward an
ectodermal cell lineage, would be a necessary step for efficient
neurogenic differentiation of MSCs.
Adherent cultures of MSCs spontaneously form rare cell
clusters similar to those formed by human embryonic cells (ES).
This indicates that a subpopulation ofMSCsmay have embryonic
characteristics and multipotential differentiation properties.
Recently, researchers have identified an MSC population which
is resistant to severe cellular stress conditions (Kuroda et al.,
2010). These cells termed as multilineage differentiating stress
enduring (MUSE) cells can be isolated by FACS analysis since
they express both the mesenchymal CD105 and the embryonic
SSEA3 markers (Kuroda et al., 2013). MUSE cells also express a
variety of pluripotency markers and can efficiently differentiate
into ectodermal and endodermal cell lineages (Heneidi et al.,
2013). We propose that MUSE-derived YFP-ATXN1Q82 MSCs
differentiated toward neuronal cells, would be an excellent cell
model for SCA1. Given their high proliferative capacity, these
cells could be used for the identification of novel drugs in cell-
based assays, which should be further validated in iPSC-derived
neuronal models.
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FIGURE 1 | Human mesenchymal stem cells overexpressing YFP-ATXN1Q82. (A) Optical microscopy (brightfield) (B) Fluorescence microscopy.
YFP-ATXN1Q82 protein aggregates are shown in green. Nuclei are stained with DAPI (blue), (C) Merged image (Scale bar = 25µM).
Stem Cell-based Therapies of polyQ
Diseases
Development of therapies for polyQ diseases focuses mainly on
the identifiaction of novel drugs through compound screening.
Potential targets for such screenings include chaperones, caspases
and polyglutamine proteins themselves. Several drugs have been
used so far in clinical trials. However, the lack of a clear
improvement of the disease symptoms underlines the importance
for the development of novel effective therapies.
Novel therapeutic approaches focus on the development of
cell replacement therapies for polyQ diseases. Such therapies
aim in either replacing damaged neurons or activating the
endogenous neurogenesis mechanisms of the brain. Stem cells
represent a promising tool for regenerative medicine and the
treatment of human disorders. In the following sections, we are
going to present stem-cell transplantation attempts in models of
polyQ diseases focusing on those using MSCs.
In the case of HD, medium spiny neurons (MSNs) of the
striatum are selectively lost. Attempts to replace these neurons
have been made using fetal striatal tissue or striatal progenitors
derived from human ES cells (Aubry et al., 2008). Although, these
attempts showed promising results in rodent models of striatal
neuronal loss, similar transplantations in clinical trials failed
to significantly mitigate the symptoms of the disease. Grafted
cells showed little integration in the affected regions of the brain
(Benraiss and Goldman, 2011). Since these attempts involved
allogeneic transplantation to patients, several issues need to be
reconsidered. A key point is the establishment of an appropriate
immunosuppression protocol to efficiently avoid graft
rejection.
Transplantation of neurons derived from iPSCs is another
option for cell replacement strategies. Such cells could be
used for autologous transplantations since they are generated
by the patient‘s own fibroblasts. However, there are concerns
that need to be taken into account, including the need for
genetic correction of the polyQ gene in generated neurons. A
recent study reported the generation of genetically corrected
iPSCs from HD patients. iPSC-derived neural stem cells showed
reversed disease phenotypes and striatal differentiation in vivo
(An et al., 2012), indicating their potential therapeutic value.
At the moment, there is a limited number of studies evaluating
the effect of iPSC transplantation in animal models of polyQ
diseases. Those to follow would have to deal with the problem
of efficient cell integration into host neuronal circuitry. Despite
that, iPSCs represent an ideal source of patient-specific neurons
for cell replacement therapies.
A different approach focuses on the use of adult stem cells
for restoration of normal brain function in polyQ diseases.
Chintawar et al. evaluated the effect of neural precursor cells
(NPCs) in a SCA1 mouse model that displays progressive
ataxia and PC loss. NPCs were stereotactically engrafted into
the cerebellum of SCA1 mice which showed improved motor
skills after transplantation. Transplanted NPCs were detected
in close vicinity to the molecular layer of PCs suggesting that
their neuroprotective effect was mediated by direct contact with
host neurons (Chintawar et al., 2009). Furthermore, NPCs were
shown to functionally integrate into the host neural circuitry and
to form gap junctions that mediate neuroprotection (Jaderstad
et al., 2010). Interestingly, the effect of NPCswasmore prominent
in older animals suggesting that these cells may be protective
mainly in mice with significant cell loss.
Other adult stem cell populations, such as MSCs, also exert
neuroprotective effects in rodent models of neurodegenerative
diseases. MSCs have the advantage of high proliferative capacity
and low expression of major histocompatibility complex antigens
(Pittenger et al., 1999). Thus, they could be used for allogeneic
transplantations with minimum risk for graft rejection. In the
polyQ field, MSCs have been used in several studies summarized
in Table 1. Transplantation of MSCs in the brain has raised
concerns about the safety of the procedure. These concerns
are based on the assumption that MSCs are not of neuronal
origin and may form tumor-like cell clusters when grafted in a
neuronal environment. However, recent work showed that MSCs
are normally present in neuronal tissue and are detected in the
vascular niche of the adult human brain (Paul et al., 2012). Their
role is not clear but they may support neovascularization in the
case of brain injury.
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TABLE 1 | Effect of MSCs transplantation in polyQ disease models.
Type of cells Number of cells Administration route Disease model Observations References
BM-MSCs 0.1× 106 Transplantation into the
striatum
HD – N17182Q mice 1. Decrease of striatum atrophy
2. Proliferation and differentiation of
endogenous neural stem cells
Snyder et al., 2010
BM-MSCs 0.2× 106 Transplantation into the
striatum
HD – R6/2-J2 mice 1. Neuronal differentiation of MSCs
2. Migration of MSCs to the damaged
area
3. Increased levels of chemokines
and angiogenesis markers
Lin et al., 2011
NTF-MSCs 0.1× 106 Transplantation into the
striatum
HD – R6/2-J2 mice 1. Temporary improvement in motor
function
2. Extension of transgenic mice life
span
Sadan et al., 2012a
BM-MSCs 0.4× 106 Transplantation into the
striatum
HD – HD 51 CAG rats 1. Long-term behavioral benefits Rossignol et al., 2013
BM-MSCs 0.1× 106 Transplantation into the
striatum
QA striatal lesioned rats 1. Increased levels of stem cell factor
protein
Bantubungi et al., 2008
BM-MSCs 2× 106 Intravenous injection QA striatal lesioned rats 1. Reduction of behavioral
abnormalities
Edalatmanesh et al., 2009
BM-MSCs 0.25× 106 Transplantation into the
cerebellum
Cerebellar ataxia –
Lurcher mice
1. Expression of neurotrophic factors
by MSCs
2. Increased number of Purkinje cells
3. Fusion with Purkinje cells
4. Improvement of motor behavior
Jones et al., 2010
UC-MSCs Repeated doses of
2× 106 cells/week
Intravenous injection Cerebellar ataxia – ICR
mice injected with Ara-C
1. Increased levels of neurotrophic
factors
2. Improvement of motor function in
ataxic mice
Zhang et al., 2011
BM-MSCs 0.6× 106 Intrathecal injection SCA1 – B05 line (Q82)
mice
1. Mitigation of cerebellar neuronal
disorganization
2. Suppression of PC dendrites
atrophy
3. Improvement of motor behavior
Matsuura et al., 2013
BM-MSCs 42× 106 cells/ kg
of body weight
Intravenous injection SCA2- C57BL/6J SCA2
mice
1. Neuroprotective effect on
cerebellar PCs
Chang et al., 2011
BM-MSCs
overexpressing
BDNF or NGF
0.3× 106 Transplantation into the
striatum
HD – YAC 128 mice 1. Overexpression of neurotrophins
by MSCs
2. Improvement of motor behavior
Dey et al., 2010
BM-MSCs
overexpressing
DnaJB4 or Pcbp3
0.05× 106 Injection to right
retro-orbital sinus
SCA1 – SCA1154Q/2Q
mice
1. Fusion with Purkinje cells
2. Decreased number of nuclear
inclusions
3. Increased number of surviving PCs
Chen et al., 2011
Table shows the type and number of cells that were used in each experiment (BM, bone marrow; UC, umbilical cord; NTF, neurotrophic factors-secreting). It also shows the administration
route, the disease model and the outcome of the assay as described in the relevant publication.
When transplanted into the cerebellum of Lurcher mice, a
model of cerebellar ataxia, MSCs rescued Purkinje cells. Treated
mice also presented significant improvement in their motor
behavior. Histological analysis indicated that donor cells had
migrated throughout the cerebellum. Many of them were located
adjacent to the PC layer and expressed neurotrophic factors.
Also, a significant increase in the number of PCs was observed.
These results suggest that MSCs migrate toward areas where
neurodegenerative processes occur and may rescue degenerating
cells through cell-trophic effects (Jones et al., 2010).
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Using a SCA1 mouse model, Matsuura et al. (2013) showed
that intrathecal injection of MSCs could tone down the cerebellar
neuronal disorganization, suppress the atrophy of PC dendrites
and normalize motor coordination deficits in mice. More
importantly, two studies performed in an HDmodel showed that
MSCs survived for several weeks after transplantation into the
striatum, partially differentiated into neuronal cell populations
and activated endogenous neurogenesis mechanisms. Increased
levels of neurotrophins were detected in parallel with a migration
of endogenous neural stem cells to the lesioned areas (Snyder
et al., 2010; Lin et al., 2011). These findings indicate that
transplanted MSCs may reduce striatal damage in HD through
the release of neurotrophic factors. This conclusion is further
supported by experiments with neurotrophic factors-secreting
MSCs (NTF-MSCs) which produce high levels of BDNF, NGF,
and VEGF. Using the quinolinic acid (QA) lesion model of HD,
Sadan et al. (2012b) showed that NTF-MSCsmigrated toward the
lesioned striatum and attenuated QA excitotoxicity.
Several lines of evidence indicate that transplantation of
MSCs in the brain promotes synaptic transmission of neuronal
networks and regeneration of the Purkinje cell layer. These
events may be attributed to direct communication of MSCs
with damaged neurons and delivery of trophic factors through
exosomes, gap junctions or tunneling nanotubules (Nakamura
et al., 2014). In several cases, MSCs were observed to fuse with
damaged PCs in vivo, an event monitored by the formation of
heterokaryons (Bae et al., 2007). These heterokaryons display PC
identities and have similar morphology and electrophysiological
properties (Weimann et al., 2003; Johansson et al., 2008; Kemp
et al., 2011). Such events are rare under normal conditions.
However, they are markedly increased in the presence of
inflammatory cytokines within a damaged tissue. MSCs have
an earlier effect in promoting neuronal survival compared to
NPCs (Matsuura et al., 2013). This observation may be partially
explained by their fusion with damaged neurons. It also suggests
that these events are physiologically important and protective in
neurodegenerative diseases (Singec and Snyder, 2008).
Genetically Engineered MSCs for
Therapeutic Approaches in polyQ Diseases
Since, MSCs fuse with damaged neurons, researchers have
exploited their propensity; they have geneticallymodified them in
order to deliver bioactive factors into cells at risk. This approach
confers advantages over systemic administration or direct
injection of e.g. genetically-modified viruses. Transplantation
of genetically engineered MSCs (GE-MSCs) combines the
advantages of cell and gene therapy. These cells have an intrinsic
ability to express cell-trophic cytokines which promote neuronal
growth, reduce release of free radicals and suppress inflammation
(Olson et al., 2011b). At the same time, GE-MSCs may migrate
to damaged brain areas and deliver their cargo directly to
degenerating cells.
In the polyQ field, three attempts using GE-MSCs have
been described. In HD, decreased levels of GDNF, NGF and
BDNF in the brain are commonly observed. These neurotrophins
contribute to growth and survival of neurons; therefore, their
overexpression in vivo seems to be a logical strategy for the
attenuation of the disease. Dey et al. transplanted GE-MSCs
expressing BDNF or NGF into the striata of YAC128 transgenic
mice and showed that transplanted mice presented less
behavioral deficits. Mice receiving GE-MSCs had significantly
less neuronal loss within the striatum surrounding the transplant
area than control groups (Dey et al., 2010).
MSCs could be also used for RNAi transfer against polyQ
proteins into damaged neurons. Olson et al. followed a similar
strategy in order to suppress expression of mutant huntingtin
(HTT) in neuronal cells. They generated MSCs expressing
shRNA antisense to HTT and co-cultured them with cells
expressing HTT142Q. Levels of HTT142Q were markedly
reduced in neuronal cells indicating the direct communication
and exchange of RNAi molecules between MSCs and HTT142Q
expressing cells (Olson et al., 2011a).
Based on the property of MSCs to fuse with host PCs, Chen
at al. tested a gene delivery approach for SCA1. Transplantation
of GE-MSCs that overexpress chaperones attenuated disease
pathogenesis in SCA1 mice. Binucleated Purkinje heterokaryons
were detected and successfully expressed the modifier genes
in vivo. Researchers also observed decreased number of nuclear
inclusions containing polyQ ATXN1 aggregates and increase in
the number of surviving Purkinje neurons (Chen et al., 2011).
Taken together, these results indicate the potential use of GE-
MSCs as gene/RNAi delivery vehicles in degenerating neurons.
They also indicate the challenges that need to be addressed,
such as the appropriate genetic modification method, number of
cells, route and timing of transplantation and most importantly,
selection of specific genes to overexpress in MSCs.
Viruses are commonly used to produce GE-MSCs. Despite
their high transfection efficiency, nuclear transport of viral
vectors and transgene expression may be impaired due to
phosphorylation of the vector capsid and its subsequent
degradation by the host proteasome machinery (Zhong et al.,
2007). Therefore, non-viral methods may be more efficient for
the generation and survival of GE-MSCs. The Sleeping Beauty
transposon system is one of them; it has major advantages
over viral vectors including high transgene expression, ease of
handling and more importantly biosafety (Galla et al., 2011). In
addition, it can be used for the genetic modification of MSCs and
the generation of cell lines stably expressing a gene of interest
(Petrakis et al., 2012a).
Concerning parameters such as the route of administration,
number of cells to be transplanted and timing of the
transplantation during disease progression, one should consider
that MSCs should (a) reach the injured area and (b) survive for
a substantial period of time in order to exert their therapeutic
effect. MSCs are usually attracted by chemokines released by
degenerating cells and activated microglia (Aarum et al., 2003).
Following systemic administration, MSCs should cross the
blood-brain-barrier in order to reach the brain. Therefore, a
local administration ofMSCswould be preferable considering the
restrictions of extensive cell migration into the central nervous
system. On the other hand, such a procedure is invasive and
may damage the multilayer organization of neuronal tissue.
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Intrathecal administration of MSCs may represent an alternative
and less invasive strategy (Matsuura et al., 2013). A critical
point in such attempts is the survival of transplanted cells which
may greatly influence their neuroprotective effect. Experimental
evidence indicate that GE-MSCs are able to survive in vivo for
a limited period of time compared to NPCs (Petrakis et al.,
unpublished data). Additionally, the effect of MSCs is more
prominent when repeated doses of cells are administered (Zhang
et al., 2011). These data indicate a limitation of GE-MSC
transplantation; they also demonstrate the need to develop cell
lines with a high survival potential that would not cause any
adverse effect after in vivo transplantation.
GE-MSCs should also encode for genes that strongly suppress
polyQ-induced neurodegeneration preferably at early stages of
the disease. In the last years, several studies have described
modifier genes that modulate cytotoxicity and aggregation
of mutant proteins. Some of them, have a well-defined
mode of action, suppressing the formation of toxic oligomers
that are early formed in polyQ diseases and correlate with
neuronal cell loss. For example, components of the ubiquitin-
proteasome machinery upregulate proteasomal activity and
their overexpression in damaged neurons may induce clearance
of polyQ protein aggregates. At the molecular level, the
interaction of polyQ ATXN1 with proteins like PUM1 or
RBM17 is protective in SCA1 models (Lim et al., 2008; Petrakis
et al., 2012b). Therefore, MSC-mediated delivery of e.g. PUM1
or RBM17 genes in Purkinje cells might favor protective
protein interactions, prohibit toxic interactions and inhibit
neurodegeneration in SCA1.
Conclusions
Stem cells are a valuable tool to face polyQ diseases. Different
types of them have different modes of actions. iPSCs can
give rise to patient-specific neurons; together with NPCs they
can be used for cell replacement therapies. MSCs can be
easily isolated and modified to overexpress polyQ proteins,
serving as disease models for drug discovery. When transplanted
in vivo, GE-MSCs tend to home into injury sites and fuse with
damaged neurons, delivering protective molecules. These cells
have also the ability to promote neuronal survival. Potentially,
co-transplantation of iPSCs and GE-MSCs may promote the
engraftment of patient-specific iPSC-derived neurons and the
survival of endogenous neurons in damaged brain areas.
We strongly believe that stem cells hold great promise for
the development of novel cell-based therapies for polyQ
diseases.
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